Designer GLP1 poly-agonist peptides in the management of diabesity

References

• WHO: Obesity and overweight [internet]. World Health Organisation; 2021. [cited 2022 Dec 30]; Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• Golubic R, Barber TM, Caleyachetty R. Obesity definition for personalised treatment of type 2 diabetes. Lancet. 2022;399(10342):2189.
   PubMed Web of Science ®Google Scholar
• Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(7):419–426. DOI:10.1016/S2213-8587(21)00088-7
   PubMed Web of Science ®Google Scholar
• Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111.
   PubMed Web of Science ®Google Scholar
• LaBarre J. Sur les possibilités d’un traitement du diabète par I’incrétine. Bull Acad R Med Belg. 1932;12:620–634.
   Google Scholar
• Avery AR, Duncan GE. Heritability of type 2 diabetes in the Washington State Twin Registry. Twin Res Hum Genet. 2019;22(2):95–98.
   PubMed Web of Science ®Google Scholar
• Willemsen G, Ward KJ, Bell CG, et al. The concordance and heritability of type 2 diabetes in 34,166 twin pairs from international twin registers: the discordant twin (DISCOTWIN) Consortium. Twin Res Hum Genet. 2015;18(6):762–771. DOI:10.1017/thg.2015.83
   PubMed Web of Science ®Google Scholar
• Hanson P, Weickert MO, Barber TM. Obesity: novel and unusual predisposing factors. Ther Adv Endocrinol Metab. 2020;11:2042018820922018.
   Web of Science ®Google Scholar
• Elder PJD, Ramsden DB, Burnett D, et al. Human amylase gene copy number variation as a determinant of metabolic state. Expert Rev Endocrinol Metab. 2018;13(4):193–205.
   PubMed Web of Science ®Google Scholar
• Barber TM, Bhatti AA, Elder PJD, et al. AMY1 gene copy number correlates with glucose absorption and visceral fat volume, but not with insulin resistance. J Clin Endocrinol Metab. 2020;105(10):e3586–3596. DOI:10.1210/clinem/dgaa473
   Google Scholar
• Brown E, Wilding JPH, Barber TM, et al. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816–828.
   PubMed Web of Science ®Google Scholar
• Hanson P, Randeva H, Cuthbertson DJ, et al. The DAPA-DIET study: metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort study. Endocrinol Diabetes Metab. 2022;5(6):e381. DOI:10.1002/edm2.381
   PubMedGoogle Scholar
• Davies MJ, Russell-Jones D, Barber TM, et al. Glycaemic benefit of iGlarlixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diab Obes Metab. 2019;21(8):1967–1972. DOI:10.1111/dom.13791
   PubMed Web of Science ®Google Scholar
• Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022;127:154937.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. DOI:10.1186/s12933-021-01366-8
   PubMed Web of Science ®Google Scholar
• Brown E, Wilding JPH, Alam U, et al. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Ann Med. 2021;53(1):2072–2089.
   PubMed Web of Science ®Google Scholar
• Ma H, Lin YH, Dai LZ, et al. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807.
   Google Scholar
• Gribble FM. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc. 2012;71(4):456–462.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23.
   PubMed Web of Science ®Google Scholar
• Conlon JM, O’Harte FPM, Flatt PR. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - a review. Peptides. 2022;147:170706.
   PubMed Web of Science ®Google Scholar
• Capozzi ME, DiMarchi RD, Tschöp MH, et al. Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev. 2018;39(5):719–738.
   PubMed Web of Science ®Google Scholar
• Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–209.
   PubMed Web of Science ®Google Scholar
• Barber TM, Valsamakis G, Mastorakos G, et al. Dietary influences on the microbiota–gut–brain axis. Int J Mol Sci. 2021;22(7):3502. DOI:10.3390/ijms22073502
   PubMed Web of Science ®Google Scholar
• Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305–312.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diab Obes Metab. 2018;20(Suppl 1):5–21.
   PubMed Web of Science ®Google Scholar
• Buchan AM, Polak JM, Capella C, et al. Electron immunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978;56(1):37–44.
   PubMedGoogle Scholar
• Baggio LL, Drucker DJ. Biology of incretins: gLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282(3):G424–31.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
   PubMed Web of Science ®Google Scholar
• Jalleh RJ, Jones KL, Rayner CK, et al. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. 2022;65(12):1981–1993.
   PubMed Web of Science ®Google Scholar
• Watson LE, Xie C, Wang X, et al. Gastric emptying in patients with well-controlled type 2 diabetes compared with young and older control subjects without diabetes. J Clin Endocrinol Metab. 2019;104(8):3311–3319.
   PubMed Web of Science ®Google Scholar
• Xie C, Huang W, Wang X, et al. Gastric emptying in health and type 2 diabetes: an evaluation using a 75 g oral glucose drink. Diabet Res Clin Pract. 2021;171:108610.
   PubMed Web of Science ®Google Scholar
• Barber TM, Begbie H, Levy J. The incretin pathway as a new therapeutic target for obesity. Maturitas. 2010;67(3):197–202.
   PubMed Web of Science ®Google Scholar
• Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967;46(12):1954–1962.
   PubMed Web of Science ®Google Scholar
• Stožer A, Paradiž Leitgeb E, Pohorec V, et al. The role of CAMP in beta cell stimulus-secretion and intercellular coupling. Cells. 2021;10(7):1658.
   PubMed Web of Science ®Google Scholar
• Graaf C, Donnelly D, Wootten D, et al. Glucagon-Like Peptide-1 and Its Class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013.
   PubMed Web of Science ®Google Scholar
• Wu S, Gao L, Cipriani A, et al. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials. Diab Obes Metab. 2019;21(4):975–983.
   PubMed Web of Science ®Google Scholar
• Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19.
   PubMed Web of Science ®Google Scholar
• Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58(12):2851–2862.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.
   Web of Science ®Google Scholar
• Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994;51(1):63–74.
   PubMedGoogle Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
   PubMed Web of Science ®Google Scholar
• El Eid L, Reynolds CA, Tomas A, et al. Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics. Pharmacol Res. 2022;184:106411.
   PubMed Web of Science ®Google Scholar
• Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
   PubMed Web of Science ®Google Scholar
• An Z, Prigeon RL, D’Alessio DA. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2013;98(12):4702–4708.
   PubMed Web of Science ®Google Scholar
• Wu T, Ma J, Bound MJ, et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes. 2014;63(8):2776–2787.
   PubMed Web of Science ®Google Scholar
• Gerich JE. Physiology of glucagon. Int Rev Physiol. 1981;24:243–275.
   PubMedGoogle Scholar
• Kleinert M, Sachs S, Habegger KM, et al. Glucagon regulation of energy expenditure. Int J Mol Sci. 2019;20(21):5407.
   Web of Science ®Google Scholar
• Janah L, Kjeldsen S, Galsgaard KD, et al. Glucagon receptor signaling and glucagon resistance. Int J Mol Sci. 2019;20(13):3314.
   Web of Science ®Google Scholar
• Drucker DJ. Mini review: the glucagon-like peptides. Endocrinology. 2001;142(2):521–527.
   PubMed Web of Science ®Google Scholar
• Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691.
   PubMedGoogle Scholar
• Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44(6):1433–1442.
   PubMed Web of Science ®Google Scholar
• Asano M, Sekikawa A, Kim H, et al. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes. Diab Obes Metab. 2021;23(8):1859–1867.
   PubMed Web of Science ®Google Scholar
• Xiao C, Pavlic M, Szeto L, et al. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes. 2011;60(2):383–390.
   PubMed Web of Science ®Google Scholar
• Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):G183–8.
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Sun C, Athanacio J, et al. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Diab Obes Metab. 2015;17(1):61–73.
   PubMed Web of Science ®Google Scholar
• Hornigold DC, Roth E, Howard V, et al. A GLP-1: cCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice. Appetite. 2018;127:334–340.
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650–654.
   PubMed Web of Science ®Google Scholar
• le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–114.
   PubMed Web of Science ®Google Scholar
• Milliken BT, Elfers C, Chepurny OG, et al. Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis. J Med Chem. 2021;64(2):1127–1138.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rahematpura S, Ragnini KH, et al. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. Neuropharmacology. 2021;192:108599.
   PubMed Web of Science ®Google Scholar
• Østergaard S, Paulsson JF, Kjaergaard Gerstenberg M, et al. The Design of a GLP-1/PYY dual acting agonist. Angew Chem Int Ed Engl. 2021;60(15):8268–8275.
   PubMed Web of Science ®Google Scholar
• Yang Q, Tang W, Sun L, et al. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y(2) Receptor Agonists. J Med Chem. 2022;65(20):14201–14220.
   PubMed Web of Science ®Google Scholar
• Rosete BE, Wendel D, Horslen SP. Teduglutide for pediatric short bowel syndrome patients. Expert Rev Gastroenterol Hepatol. 2021;15(7):727–733.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab. 2001;86(4):1759–1764.
   PubMed Web of Science ®Google Scholar
• Olsen MB, Hövelmann U, Griffin J, et al. 335-OR: dapiglutide, a Once-Weekly GLP-1R/GLP-2R dual agonist, was safe and well tolerated and showed dose-dependent body weight loss over four weeks in healthy subjects. Diabetes. 2022;71(Supplement_1):335–OR.
   Web of Science ®Google Scholar
• Reiner J, Thiery J, Held J, et al. The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel. Ann N Y Acad Sci. 2022;1514(1):132–141.
   PubMed Web of Science ®Google Scholar
• Reiner J, Berlin P, Held J, et al. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr. 2022;46(5):1107–1118.
   PubMedGoogle Scholar
• Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47(3):370–376.
   PubMed Web of Science ®Google Scholar
• Madsen KB, Askov-Hansen C, Naimi RM, et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul Pept. 2013;184:30–39.
   PubMed Web of Science ®Google Scholar
• Pan Q, Lin S, Li Y, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202.
   PubMed Web of Science ®Google Scholar
• Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 2022;34(1):59–74.e10.
   PubMed Web of Science ®Google Scholar
• Li Y, Glotfelty EJ, Namdar I, et al. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Exp Neurol. 2020;324:113113.
   PubMed Web of Science ®Google Scholar
• Li T, Jiao JJ, Hölscher C, et al. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer’s disease. Hippocampus. 2018;28(5):358–372.
   PubMed Web of Science ®Google Scholar
• Zhao S, Yan Z, Du Y, et al. A GLP-1/glucagon (GCG)/CCK(2) receptors tri-agonist provides new therapy for obesity and diabetes. Br J Pharmacol. 2022;179(17):4360–4377.
   PubMed Web of Science ®Google Scholar
• WHO: Accelerating action to stop obesity [internet]. World Health Organisation; 2022. [cited 2022 Dec 30]; Available from: https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity#:~:text=Effective%20steps%20include%20restricting%20the,access%20to%20affordable%2C%20healthy%20food.
   Google Scholar
• Safaei M, Sundararajan EA, Driss M, et al. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136:104754.
   PubMed Web of Science ®Google Scholar
• Sánchez-Garrido MA, Brandt SJ, Clemmensen C, et al. GLP-1/Glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851–1861.
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Telem DA, Kushner RF, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–887.
   PubMed Web of Science ®Google Scholar
• Oduro-Donkor D, Turner MC, Farnaud S, et al. Modification of fecal microbiota as a mediator of effective weight loss and metabolic benefits following bariatric surgery. Expert Rev Endocrinol Metab. 2020;15(5):363–373.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ren Q, Jiao S, et al. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. Eur J Med Chem. 2022;229:114061.
   PubMed Web of Science ®Google Scholar
• Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53(suppl_3):S233–8.
   PubMedGoogle Scholar
• Jorsal T, Rungby J, Knop FK, et al. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2015;16(1):1.
   Web of Science ®Google Scholar
• Bello NT, Kemm MH, Ofeldt EM, et al. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol. 2010;299(3):R945–52.
   PubMed Web of Science ®Google Scholar
• Behary P, Tharakan G, Alexiadou K, et al. Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care. 2019;42(8):1446–1453.
   PubMed Web of Science ®Google Scholar
• Zhang X, Young RL, Bound M, et al. Comparative Effects Of Proximal And Distal Small Intestinal Glucose Exposure On Glycemia, Incretin Hormone Secretion, And The Incretin Effect In Health And Type 2 Diabetes. Diabetes Care. 2019;42(4):520–528.
   PubMed Web of Science ®Google Scholar
• Bader M, Li Y, Tweedie D, et al. Neuroprotective effects and treatment potential of incretin mimetics in a murine model of mild traumatic brain injury. Front Cell Dev Biol. 2019;7:356.
   PubMed Web of Science ®Google Scholar
• Yang X, Qiang Q, Li N, et al. Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research. Front Neurol. 2022;13:844697.
   PubMed Web of Science ®Google Scholar
• Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington’s disease. Diabetes. 2009;58(2):318–328.
   PubMed Web of Science ®Google Scholar